Sabra Health Care REIT (SBRA) opened Q1 2026 with Funds From Operations of US$95.9 million, set against a backdrop of trailing twelve month net income of US$155.6 million and Basic EPS of US$0.64. Over the past reported periods, revenue moved from US$702.6 million on a trailing basis in Q4 2024 to US$775.8 million by Q4 2025, while trailing net income increased from US$126.7 million to US$155.6 million as margins rose from 18% to 20.1%. For investors, the combination of higher earnings, expanding profitability and the latest FFO figure puts the focus on how durable these margin gains may be from this point.

See our full analysis for Sabra Health Care REIT.

With the recent earnings release in place, the next step is to see how these numbers align with prevailing market views on Sabra and where the data may start to challenge those narratives.

FFO Trend Points To Consistent Cash Generation

• Funds From Operations over the last twelve months is US$370.7 million, up from US$321.6 million a year earlier, with Q1 2026 FFO at US$95.9 million compared with US$85.2 million in Q4 2024.
• Consensus narrative highlights strong demand for senior housing and healthcare facilities, and the FFO path lines up with that view:
  • Revenue on a trailing basis moved from US$702.6 million to US$775.8 million while net income went from US$126.7 million to US$155.6 million, which is consistent with the idea of higher occupancy and rent levels supporting cash flow.
  • At the same time, FFO has risen by roughly US$49.1 million over the trailing twelve months, which supports the bullish angle that Sabra is converting that demand into recurring cash available to support operations and distributions.

Sabra’s recurring cash picture is only one side of the story; the share price and valuation multiples tell you how much of that is already baked in at today’s US$20.66 price, and the community debate digs into those expectations in more detail 📊 Read the what the Community is saying about Sabra Health Care REIT..

20.1% Net Margin Meets Richer P/E

• Trailing net profit margin is 20.1%, up from 18% a year earlier, while the trailing P/E of 33.5x sits above the Global Health Care REITs average of 24.3x and below the peer average of 83.3x.
• Bulls argue that this kind of profitability justifies a stronger valuation, and the recent numbers partly support that view but also set a higher bar:
  • Net income over the last twelve months is US$155.6 million against revenue of US$775.8 million, which matches the consensus view that margin improvement is flowing through from tighter supply in senior housing and better rent coverage.
  • At the same time, the current share price of US$20.66 versus an analyst price target of US$22.00 and a DCF fair value of US$53.06 shows that, even with a relatively high P/E, valuation signals in the data set are mixed and leave room for different interpretations of how durable these margins will be.

Stronger reported margins and mixed valuation signals have some investors asking whether the optimistic thesis goes far enough or still leaves substantial room for surprises in Sabra’s story 🐂 Sabra Health Care REIT Bull Case.

Dividends And Interest Coverage Remain Pressure Points

• The risk summary flags that interest payments are not well covered by earnings and that the dividend track record over the last year has been unstable, even as earnings grew 22.8% and margins reached 20.1%.
• Bears focus on these funding pressures and the high payout ratio, and the recent data gives them concrete talking points:
  • With earnings of US$155.6 million and net margin of 20.1%, the company is profitable, but the comment that interest costs are not well covered means more of those earnings are tied up in servicing debt than many investors might like.
  • The mention of an unstable dividend and a payout ratio around 79% of AFFO in the broader narrative set suggests limited room to self fund reinvestment or reduce leverage, which fits the cautious view that income reliability and balance sheet strength are key watch items.

For readers who are most focused on income reliability and balance sheet risk, the cautious narrative unpacks these dividend and interest coverage concerns in far more depth 🐻 Sabra Health Care REIT Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Sabra Health Care REIT on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of positives and concerns in the data, it makes sense to move quickly, review the numbers yourself, and weigh both sides. To see the balance of potential upside and the key watch points in one place, start with these 3 key rewards and 2 important warning signs

See What Else Is Out There

High payout ratios, interest that is not well covered by earnings, and an unstable dividend track record make Sabra’s income profile and balance sheet feel stretched.

If those pressure points give you pause, compare Sabra with companies that show stronger financial cushions and more resilient income streams using the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.